KaloBios Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies

Published: Mar 23, 2011

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneeredâ„¢ monoclonal antibody, in EphA3-expressing hematologic malignancies.

Back to news